Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Akero Therapeutics (AKRO) stock soared 115% after the company reported positive long-term results from a Phase 2b study of ...
Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
Citi analyst Jonathan Woo says Akero Therapeutics (AKRO)’ 96-week data update from its SYMMETRY trial of efruxifermin for patients with ...
In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
US clinical-stage liver disease focused biotech Akero Therapeutics saw its shares almost double to $51.71 yesterday, after it ...
clinicaltrialsarena on MSN3d
Akero’s cirrhosis treatment shows promise in Phase IIb studyAkero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback